Results 141 to 150 of about 1,054 (155)

RIMEGEPANT FOR TREATMENT OF HUMAN CORONAVIRUS INFECTION

2023
TEIXEIRA SARAMAGO ANA MARGARIDA, GONÇALVES MATOS LUÍS RUTE MARGARIDA, PAIS DE FARIA DE ANDRADE ARRAIANO CECÍLIA MARIA, SILVA SOUZA CAIO, PEREIRA LOUSA DIANA ANDREIA, SIMÕES LOUREIRO NUNES SOARES CLÁUDIO MANUEL, SOUSA PINTO TORRES FEVEREIRO MIGUEL AGOSTINHO, FERREIRA HENRIQUES DE OLIVEIRA MOURÃO ANA   +7 more
openaire   +1 more source

Rimegepant bei Migräne effektiver als Placebo

Neurologie up2date, 2020
openaire   +1 more source

Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

New England Journal of Medicine, 2019
Gene M Dubowchik, Richard B. Lipton
exaly  

RIMEGEPANT FOR CGRP RELATED DISORDERS

2019
CORIC VLADIMIR, CROOP ROBERT
openaire   +4 more sources

ORAL FAST-DISPERSING DOSAGE FORM OF RIMEGEPANT

2021
CORIC VLADIMIR, CONWAY CHARLES M, CROOP ROBERT, FROST MARIANNE   +3 more
openaire   +2 more sources

A Comparison of the Persistence of Acute Treatment With Rimegepant Versus Oral Triptans in Patients With Migraine: A Retrospective Analysis of US Claims Data

Cephalalgia
Joanna Atkinson, Stewart J Tepper, Feng Dai   +2 more
exaly  

A 52-Week Open-Label Extension Study to Evaluate the Safety and Efficacy of Oral Rimegepant for the Preventive Treatment of Migraine

Headache
Richard B. Lipton, Alexandra Thiry, David Kudrow   +2 more
exaly  

Rimegepant, wenn Triptan nicht möglich?

InFo Neurologie + Psychiatrie
openaire   +1 more source

4CPS-155 Efficacy of rimegepant and atogepant in migraine prophylaxis

Section 4: Clinical pharmacy services
I Corriente Gordón, E Paradela Garcia, A Romero Ruiz, E Sánchez Gómez, MD Santos Rubio   +4 more
openaire   +1 more source

Evaluation of Rimegepant Utilization Patterns and Patient Characteristics Among New Users: A United States Administrative Claims-Based Study

Current Medical Research and Opinion
Jessica Ailani, Feng Dai, Lucy Abraham
exaly